Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Navitoclax-piperazine (ABT-263-piperazine) is an inhibitor of B-cell lymphoma extra large (BCL-XL).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 36,500 | |||
5 mg | 在庫あり | ¥ 74,500 | |||
10 mg | 在庫あり | ¥ 126,500 | |||
25 mg | 在庫あり | ¥ 199,500 | |||
50 mg | 在庫あり | ¥ 273,500 | |||
100 mg | 在庫あり | ¥ 369,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 128,500 |
説明 | Navitoclax-piperazine (ABT-263-piperazine) is an inhibitor of B-cell lymphoma extra large (BCL-XL). |
別名 | ABT-263-piperazine |
分子量 | 973.63 |
分子式 | C47H56ClF3N6O5S3 |
CAS No. | 2143096-93-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (256.77 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Navitoclax-piperazine 2143096-93-7 Apoptosis PROTAC BCL Ligands for Target Protein for PROTAC Navitoclaxpiperazine Bcl-2 Family B-cell VHL Target Protein-binding Moiety inhibit Inhibitor lymphoma ubiquitin ABT-263-piperazine ligase Navitoclax piperazine inhibitor